Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty.

[1]  A. Rumley,et al.  Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study , 1997, British journal of haematology.

[2]  G. Lowe,et al.  Clinical, biochemical, and rheologic factors affecting the outcome of infrainguinal bypass grafting. , 1996, Journal of vascular surgery.

[3]  G. Lowe,et al.  Smoking, Haemostatic Factors and the Severity of Aorto-lliac and Femoro-Popliteal Disease , 1996, Thrombosis and Haemostasis.

[4]  G. Lowe,et al.  Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease , 1996, British journal of haematology.

[5]  G. Lowe,et al.  Fibrin D-Dimer, Haemostatic Factors and Peripheral Arterial Disease , 1995, Thrombosis and Haemostasis.

[6]  G. Lowe,et al.  Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. , 1995, International angiology : a journal of the International Union of Angiology.

[7]  G. Lip,et al.  Fibrin D-dimer: a useful clinical marker of thrombogenesis? , 1995, Clinical science.

[8]  E. Vicaut,et al.  Fibrinogen after coronary angioplasty as a risk factor for restenosis. , 1995, Circulation.

[9]  G. Lowe,et al.  Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator inhibitor antigens are predictive of major ischaemic heart disease: the Caerphilly study , 1995 .

[10]  M. Laakso,et al.  Impact of Risk Factors on Limb Salvage After Angioplasty in Chronic Critical Lower Limb Ischemia , 1994, Angiology.

[11]  S Glagov,et al.  Intimal hyperplasia, vascular modeling, and the restenosis problem. , 1994, Circulation.

[12]  A. Gershlick,et al.  Absence of a prothrombotic state in restenotic patients? , 1994, Coronary artery disease.

[13]  J. Becquemin,et al.  Surgical transluminal femoropopliteal angioplasty: multivariate analysis outcome. , 1994, Journal of vascular surgery.

[14]  M. Egeblad,et al.  Cross-linked fibrin degradation products (XL-FDP) as marker of early rethrombosis in percutaneous transluminal angioplasty. , 1993, European journal of vascular surgery.

[15]  P. Donnan,et al.  Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. , 1993, Atherosclerosis.

[16]  A. Rumley,et al.  Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease , 1993, The Lancet.

[17]  C. Haudenschild,et al.  Pathobiology of restenosis after angioplasty. , 1993, The American journal of medicine.

[18]  P. Donnan,et al.  Blood Viscosity, Fibrinogen, and Activation of Coagulation and Leukocytes in Peripheral Arterial Disease and the Normal Population in the Edinburgh Artery Study , 1993, Circulation.

[19]  A. Banerjee,et al.  A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants , 1992, Thrombosis and Haemostasis.

[20]  G. Lowe.  Blood Viscosity and Cardiovascular Disease , 1992, Thrombosis and Haemostasis.

[21]  P. Shah,et al.  Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. , 1992, Circulation.

[22]  K. Huber,et al.  A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful Percutaneous Transluminal Coronary Angioplasty Is Associated with a Significantly Reduced Risk for Coronary Restenosis , 1992, Thrombosis and Haemostasis.

[23]  P. Serruys,et al.  Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet". , 1991, American heart journal.

[24]  G. Mclean,et al.  Femoropopliteal Angioplasty: Factors Influencing Long‐term Success , 1991 .

[25]  R. Califf,et al.  Racial Differences in Responses to Thrombolytic Therapy With Recombinant Tissue‐Type Plasminogen Activator: Increased Fibrin(ogen)olysis in Blacks , 1991, Circulation.

[26]  S. Armstrong,et al.  Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. , 1990, Radiology.

[27]  R. D'Agostino,et al.  Update on fibrinogen as a major cardiovascular risk factor: The framingham study , 1990 .

[28]  C. Dang,et al.  The normal and morbid biology of fibrinogen. , 1989, The American journal of medicine.

[29]  C. McCollum,et al.  Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. , 1989, BMJ.

[30]  P. Kalman,et al.  5‐year Results of a Prospective Study of Percutaneous Transluminal Angioplasty , 1987, Annals of surgery.

[31]  J. Sixma,et al.  Role of von Willebrand Factor in the Vessel Wall , 1987, Seminars in thrombosis and hemostasis.

[32]  D J Phillips,et al.  Noninvasive mapping of lower limb arterial lesions. , 1985, Ultrasound in medicine & biology.

[33]  R. Gatenby,et al.  Long-term results of transluminal angioplasty of the iliac and femoral arteries. , 1981, Archives of surgery.

[34]  R. Hye.  Trials and Tribulations of Vascular Surgery , 1998 .

[35]  T. Couffinhal,et al.  Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty. , 1993, International journal of cardiology.